作者: F. Orzan , S. Pellegatta , P. L. Poliani , F. Pisati , V. Caldera
DOI: 10.1111/J.1365-2990.2010.01132.X
关键词:
摘要: F. Orzan, S. Pellegatta, P. L. Poliani, Pisati, V. Caldera, Menghi, D. Kapetis, C. Marras, Schiffer and G. Finocchiaro (2011) Neuropathology Applied Neurobiology37, 381–394 Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas glioma stem-like cells Aims: Proteins the Polycomb repressive complex (PRC2) are epigenetic gene silencers involved tumour development. Their oncogenic function might be associated with their role stem cell maintenance. The histone methyltransferase a key member PRC2 function: we have investigated its expression gliomas. Methods:EZH2 was studied grade II–IV cells (GSC) by quantitative PCR immunohistochemistry. Effects EZH2 down-regulation were analysed treating GSC deacetylase (HDAC) inhibitor suberoylanide hydroxamic acid (SAHA) shRNA. Results: DNA microarray analysis showed that highly expressed murine human GSC. Real-time on different (n = 66) indicated more glioblastoma multiforme (GBM) than low-grade (P = 0.0013). This confirmed immunohistochemistry an independent set 106 Treatment SAHA caused significant up-regulation predicted target genes, disruption decreased marker CD133. Inhibition shRNA decrease proliferation. Conclusion: data suggest plays progression encourage therapeutic targeting these malignancies HDAC inhibitors.